L230 [L2-30] (ATCC® HB-8448)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  /  Cell Type: hybridoma: B lymphocyte  / 

Permits and Restrictions

View Permits View Restrictions

Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Cell Type hybridoma: B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.


Strain: ? (B cell); BALB/c (myeloma)

The antibody reacts with the M-23 antigen system.
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
Genes Expressed
immunoglobulin; monoclonal antibody; against a human melanoma cell line (M-23 antigen system)
Cellular Products
immunoglobulin; monoclonal antibody; against a human melanoma cell line (M-23 antigen system)
Animals were immunized with the SK-MEL-33 human melanoma cell line.
The antibody precipitates two glycoproteins (90000 and 150000 daltons)from extracts of SK-MEL-19 cells.
It reacted with all melanoma cell lines tested (n = 20), fetal and adult cultured melanocytes and various normal and neoplastic tissues.
The antibody reacts with the M-23 antigen system.
Complete Growth Medium RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, 1.0 mM sodium pyruvate supplemented with 0.1 mM nonessential amino acids, 90%; fetal bovine serum, 10%
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml.
Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
culture medium 95%; DMSO, 5%
Isotype IgG1; kappa light chain
Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation

The cells are distributed for research purposes only. The Memorial Sloan-Kettering Cancer Center releases the line subject to the following: 1.) The cells or their products must not be distributed to third parties. Commercial interests are the exclusive property of Memorial Sloan-Kettering Cancer Center. 2.) Any proposed commercial use of these cells must first be negotiated with The Director, Office of Industrial Affairs, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; phone (212) 639-6181; FAX (212) 717-3439.


Houghton AN, et al. Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J. Exp. Med. 156: 1755-1766, 1982. PubMed: 7175440

Real FX, et al. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: Specificity analysis and comparison of antigen expression in cultured cells and tissues. Cancer Res. 45: 4401-4411, 1985. PubMed: 4028024

Cairncross JG, et al. Monoclonal antibodies against melanocytes. US Patent 4,806,628 dated Feb 21 1989

Oettgen HF, et al. Monoclonal antibodies to cell surface antigens of human malignant melanoma. US Patent 4,808,704 dated Feb 28 1989